Dicerna Pharmaceuticals Announces Move to Larger Office and Lab Space in Cambridge, Massachusetts
Relocation Reflects Company's Continued Growth and Accommodates Future Expansion
February 26, 2015 07:30 AM Eastern Standard Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi therapeutics, today celebrates the opening of a new 37,000 square-foot office and state-of-the-art research and development (R&D) laboratory at 87 Cambridgepark Drive, in Cambridge's Alewife neighborhood. Mayor of Cambridge David Maher, Vice Mayor of Cambridge Dennis Benzan, State Representative Jay Livingstone, Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, Ph.D., and MassBio President & CEO Robert Coughlin will attend a reception and ribbon cutting ceremony at Dicerna this afternoon to mark this important occasion.
"Dicerna's relocation from Watertown to larger, more centrally-located office space in Cambridge reflects our continued growth and success, and accommodates future expansion plans," said Douglas M. Fambrough, Ph.D., chief executive officer of Dicerna. "Dicerna has more than doubled its footprint in the new space and now employs approximately 45 people, with plans to hire an additional 10 employees this year, and many more going forward."
The Company's new office exemplifies its entrepreneurial, employee-focused culture, with an open office plan and various meeting and workspaces, which are designed to foster innovation, communication, collaboration and teamwork.
"Today is an exciting day for Dicerna, for Cambridge, for the Commonwealth and for the many people around the world who stand to benefit from Dicerna's work," said Massachusetts Governor Charlie Baker. "We welcome Dicerna's expansion here in the Commonwealth, and look forward to their ongoing contributions to our thriving life sciences community."
Dicerna's move to Cambridge underscores its commitment to being an employer of choice in the Massachusetts life sciences sector, and to being in close proximity to world-class research, academic and healthcare institutions as well as other life sciences leaders. Dicerna will play an active role in the Alewife business community as the area undergoes a revitalization to become a mini life sciences and technology hub. The Company's new location is close to the MBTA subway and buses, the 120-acre Alewife Reservation, as well as many restaurants and services.
"With new developments at 87 Cambridgepark Drive and 200 Cambridgepark Drive, totaling 300,000 square feet, we are creating a life sciences cluster in the Alewife neighborhood, adding to the successful biotech and pharma community in Cambridge," said Stephen Lynch, principal of King Street Properties. "We are pleased to welcome Dicerna as the anchor tenant in our renovated Alewife development."
Last year was a pivotal year for Dicerna. The Company began 2014 with a successful IPO, raising $103 million. Dicerna also initiated two Phase 1 clinical trials for its DCR-MYC program in oncology, the culmination of years of focused effort to bring its Dicer substrate short-interfering RNA (DsiRNA) therapeutics into clinical development. In 2015, Dicerna will start clinical development of a second innovative medicine, DCR-PH1, which has the potential to be a functional cure for the serious and difficult-to-treat genetic disease primary hyperoxaluria type 1 (PH1).
Dicerna is currently hiring and has a number of positions available. For more information on job opportunities, please visit www.dicerna.com/careers.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have been difficult to address using conventional approaches, but where connections between targets and diseases are well understood and documented. The company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.